Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 5/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634302 | 0.82 | TDO2 (0.42) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL25328601 | 0.80 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2IDO1TDO2 | |
| SCHEMBL1634376 | 0.80 | ALDH1A1 (0.45) | PDE4BALDH1A1KDM4ESMN1; SMN2PDE4A | |
| SCHEMBL1633538 | 0.77 | NFKB1 (0.40) | KDM4EJUNNFKB1NFKB2RELA | |
| SCHEMBL30527150 | 0.77 | NQO2 (0.45) | PDE4BALDH1A1KDM4ESMN1; SMN2PDE4A | |
| SCHEMBL25903679 | 0.77 | NQO2 (0.45) | PDE4BALDH1A1KDM4ESMN1; SMN2PDE4A | |
| SCHEMBL2785564 | 0.71 | SLC40A1 (0.46) | PDE4BALDH1A1KDM4EPDE4APDE4C | |
| SCHEMBL2015792 | 0.69 | AURKA (0.48) | ALDH1A1KDM4ESMN1; SMN2NFKB1GAA | |
| SCHEMBL2860108 | 0.69 | KDM4E (0.49) | ALDH1A1KDM4ESMN1; SMN2GAANQO2 | |
| SCHEMBL30122456 | 0.69 | KDM4E (0.49) | ALDH1A1KDM4ESMN1; SMN2GAANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | PDE4B 667/4885ALDH1A1 2679/4885KDM4E 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.